UCLA Health has received certification to provide a therapy that genetically modifies patients’ own cells to attack cancer, the university announced Friday. The Food and Drug Administration approved the treatment, marketed as Yescarta, in October for patients with a type of blood cancer called large B cell lymphoma. Read more...
Photo: The treatment is a form of chimeric antigen receptor T cell therapy, in which a synthetic gene is added to T cells that recognize infectious substances and mount an immune response. (Daily Bruin file photo)






